Serum antibodies to human papillomavirus (HPV) pseudovirions correlate with natural infection for 13 genital HPV types

Faust, Helena; Jelen, Mateja M.; Poljak, Mario; Klavs, Irena; Učakar, Veronika; Dillner, Joakim

doi:10.1016/j.jcv.2012.12.004

Cited by 26 publications

(16 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study population was not HPV-na€ ve, and as a result a proportion of "incident" infections might actually have been reactivations of long-standing infections, diluting our results. Finally, there is no standardized serologic assay for detection of HPV antibodies (9,31). In a previous article, we compared 3 serologic assays, including the MIA used in the current study, and observed good correlations for both naturally induced and vaccine-derived HPV-specific antibody levels (32).…”

Section: Discussionmentioning

confidence: 53%

“…Analyses were limited to the 7 high-risk HPV types that could be detected by both the serology and DNA genotyping methods used, i.e., types 16,18,31,33,45,52, and 58. Samples positive for one or more of these 7 HPV types were designated hrHPVpositive in this article; samples negative for all of these 7 high-risk types were categorized as hrHPV-negative.…”

Section: Statistical Analysesmentioning

confidence: 99%

See 1 more Smart Citation

HPV Seroconversion Following Anal and Penile HPV Infection in HIV-Negative and HIV-Infected MSM

Mooij

Landén

Klis

et al. 2014

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background: We assessed human papillomavirus (HPV) seroconversion following anal and penile HPV infection in HIV-negative and HIV-infected men who have sex with men (MSM).Methods: MSM aged !18 years were recruited in Amsterdam, the Netherlands (2010-2011), and followed up semiannually. Antibodies against 7 high-risk HPV types in baseline and 12-month serum samples were tested using a multiplex immunoassay. Baseline, 6-, and 12-month anal and penile samples were tested for HPV DNA using the SPF 10 -PCR DEIA/LiPA 25 system. Statistical analyses were performed using logistic regression with generalized estimating equations.Results: Of 644 MSM included in the analysis, 245 (38%) were HIV-infected. Median age was 38 years for HIV-negative and 47 years for HIV-infected MSM (P < 0.001). Seroconversion against !1 of the 7 HPV types was observed in 74 of 396 (19%) HIV-negative and 52 of 223 (23%) HIV-infected MSM at risk (P ¼ 0.2). Incident [adjusted OR (aOR) 2.0; 95% confidence interval (CI), 1.1-3.4] and persistent (aOR 3.7; 95% CI, 1.5-9.5) anal HPV infections were independently associated with type-specific seroconversion in HIV-negative MSM. In HIVinfected MSM, there was a nonsignificant positive association between penile HPV infection at any time point and seroconversion (aOR 1.7; 95% CI, 0.9-3.2).Conclusions: Incident or persistent anal HPV infection was an independent determinant of seroconversion in HIV-negative MSM.Impact: Our data support that seroresponse may vary per anatomic site and that persistent HPV infections are more likely to elicit a detectable humoral immune response. Cancer Epidemiol Biomarkers Prev; 23(11); 2455-61. Ó2014 AACR.

show abstract

Section: Discussionmentioning

confidence: 53%

Section: Statistical Analysesmentioning

confidence: 99%

HPV Seroconversion Following Anal and Penile HPV Infection in HIV-Negative and HIV-Infected MSM

Mooij

Landén

Klis

et al. 2014

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…Equations and detailed parameter tables are provided (SI Appendix, Table S1). We parameterized the type-specific HPV clearance rate in women and the type-specific antibody protection against reinfection from the control arm of the PATRICIA clinical trial (26,39), the type-specific clearance rate in men from the HIM cohort study (40), the type-specific probability of developing antibodies from the Slovenian HPV prevalence survey (41), and the type-specific rate of antibody decay from the Finnish Family HPV study (42).…”

Section: Methodsmentioning

confidence: 99%

National- and state-level impact and cost-effectiveness of nonavalent HPV vaccination in the United States

Durham

Ndeffo-Mbah

Skrip

et al. 2016

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Every year in the United States more than 12,000 women are diagnosed with cervical cancer, a disease principally caused by human papillomavirus (HPV). Bivalent and quadrivalent HPV vaccines protect against 66% of HPV-associated cervical cancers, and a new nonavalent vaccine protects against an additional 15% of cervical cancers. However, vaccination policy varies across states, and migration between states interdependently dilutes state-specific vaccination policies. To quantify the economic and epidemiological impacts of switching to the nonavalent vaccine both for individual states and for the nation as a whole, we developed a model of HPV transmission and cervical cancer incidence that incorporates state-specific demographic dynamics, sexual behavior, and migratory patterns. At the national level, the nonavalent vaccine was shown to be cost-effective compared with the bivalent and quadrivalent vaccines at any coverage despite the greater per-dose cost of the new vaccine. Furthermore, the nonavalent vaccine remains cost-effective with up to an additional 40% coverage of the adolescent population, representing 80% of girls and 62% of boys. We find that expansion of coverage would have the greatest health impact in states with the lowest coverage because of the decreasing marginal returns of herd immunity. Our results show that if policies promoting nonavalent vaccine implementation and expansion of coverage are coordinated across multiple states, all states benefit both in health and in economic terms.uman papillomavirus (HPV) is the most prevalent sexually transmitted infection in the United States (1). Although more than 100 types of HPV have been identified, HPV-16 and HPV-18 are responsible for 66% of cervical cancers (2). Two vaccines, Gardasil (4vHPV) and Cervarix (2vHPV), were approved by the Food and Drug Administration in 2006 and 2009, respectively. Both of these vaccines are highly efficacious against HPV-16 and HPV-18 and are partially efficacious against other non-vaccine-targeted oncogenic serotypes (2, 3). Licensed in 2014, Gardasil-9 (9vHPV) is a new vaccine that elicits immunity to five additional oncogenic serotypes, extending protection to 80% of cervical cancers (2, 4). In 2007, the Centers for Disease Control and Prevention (CDC) recommended HPV vaccination for all girls and women aged 9-26 y (5). In 2011, this recommendation was extended to males to reduce transmission (3). In 2015, the CDC recommended that females aged 11-26 y be vaccinated with any of the three available vaccines and that males aged 11-21 y receive either 4vHPV or 9vHPV (2). Although CDC contract and private sector prices vary, the new vaccine, at a per-dose cost of $126, is approximately $13 more costly than 4vHPV and $18 more costly than 2vHPV (SI Appendix).HPV vaccination has been recommended nationwide with funding to enhance coverage provided by the CDC Prevention and Public Health Fund (PPHF) (6). Vaccine cost, the availability of subsidies, and the supplementing of federal support with state and local funds have b...

show abstract

“…Infection with certain genotypes of HPV has been linked with cervical cancer development. In china vaccines were developed to combat HPV infection, consequently, the most prevalence HPV types should be determined in each region (Arbyn et al, 2010;Faust et al, 2013). The Uyghur women who live in desert regions have the unique lifestyles and religion has the highest prevalence of cervical cancer in China.…”

Section: Introductionmentioning

confidence: 99%

Genotype Distribution and Behavioral Risk Factor Analysis of Human Papillomavirus Infection in Uyghur Women

Sui¹,

Jiao²,

Niyazi³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

We investigated the distribution of HPV genotypes in Uyghur women in Xinjiang region of China, and behavioral factors which could predispose them to HPV infection. In this cross-sectional study, women aged 15-59 years were recruited by cluster sampling method in Yutian region in 2009. Liquid-based cytology samples were analyzed centrally for HPV genotype with a linear array detector. Univariate and multivariate logistic regression analyses were performed to identify behavioral risk factors for HPV infection. A total of 883 Uyghur women were recruited successfully. The prevalence of high-risk HPV and low-risk HPV were 7.25% and 1.58%, respectively; the most common HPVs were HPV16, 51, 31, 39 and 58. We found that age of first sexual intercourse was a strong predictor for HPV infection (odds ratio of 4.01 for ≤ 15 years versus ≥25). Having sexual partners ≥ 3 was the second predictor (OR 3.69, 95% CI 2.24-7.16). Cleaning the vagina after sex showed an increased risk of HPV infection (OR 2.72; 95% CI 1.98-5.13); Using the condom showed protective factors for HPV infection (OR 0.36; 95%CI0.12-0.53). HPV16, 51, 31, 39 and 58 were the priority types; the age of first sexual intercourse was identified as a major risk factor for HPV infection. Other notable risks were number of sexual partners and cleaning the vagina after sex. Changing these behavioral risk factors could help to reduce the occurrence of cervical cancer in this population.

show abstract

Serum antibodies to human papillomavirus (HPV) pseudovirions correlate with natural infection for 13 genital HPV types

Cited by 26 publications

References 30 publications

HPV Seroconversion Following Anal and Penile HPV Infection in HIV-Negative and HIV-Infected MSM

HPV Seroconversion Following Anal and Penile HPV Infection in HIV-Negative and HIV-Infected MSM

National- and state-level impact and cost-effectiveness of nonavalent HPV vaccination in the United States

Genotype Distribution and Behavioral Risk Factor Analysis of Human Papillomavirus Infection in Uyghur Women

Contact Info

Product

Resources

About